Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug;55(4):162-172.
doi: 10.1007/s13139-021-00709-3. Epub 2021 Jul 13.

Transarterial Radioembolization Agents: a Review of the Radionuclide Agents and the Carriers

Aysheh Alrfooh  1 , Aditi Patel  2 , Sandeep Laroia  2
Affiliations
Review

Transarterial Radioembolization Agents: a Review of the Radionuclide Agents and the Carriers

Aysheh Alrfooh et al. Nucl Med Mol Imaging. 2021 Aug.

Abstract

Liver tumors, both primary and secondary to metastatic disease, remain a major challenge, with an increasing incidence. In this context, taking advantage of the dual blood supply of the liver, and the fact that liver tumors derive majority of their blood supply from the hepatic artery, intraarterial therapies are gaining popularity. Intraarterial liver-directed therapy (IALDT) is the option when the surgery is not feasible due to the number of metastases or for other reasons. Transarterial radioembolization (TARE) is a specific type of IALDT, where a carrier particle/microsphere is labeled with a radioactive substance and then is injected into hepatic artery for therapeutic purposes. As this field is rapidly evolving, with multiple agents being investigated and being introduced into clinical practice, it is hard for the practitioners and researchers to encompass all the available information concisely. This article aims to present a comprehensive review of the prominent TARE technologies.

Keywords: Carrier molecules; Hepatocellular carcinoma; Microspheres; Radionucleotides; Transarterial radioembolization.

PubMed Disclaimer

Conflict of interest statement

Conflict of InterestAysheh Alrfooh, Aditi Patel, and Sandeep Laroia declare that they have no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. doi: 10.3322/caac.21262. - DOI - PubMed
    1. Ahmed I, Lobo DN. Malignant tumours of the liver. Surgery - Oxford International Edition. 2009;27:30–37.
    1. Ronot M, Clift AK, Vilgrain V, Frilling A. Functional imaging in liver tumours. J Hepatol. 2016;65:1017–1030. doi: 10.1016/j.jhep.2016.06.024. - DOI - PubMed
    1. Page AJ, Weiss MJ, Pawlik TM. Surgical management of noncolorectal cancer liver metastases. Cancer. 2014;120:3111–3121. doi: 10.1002/cncr.28743. - DOI - PubMed
    1. Zhu RX, Seto WK, Lai CL, Yuen MF. Epidemiology of hepatocellular carcinoma in the Asia-Pacific Region. Gut Liver. 2016;10:332–339. doi: 10.5009/gnl15257. - DOI - PMC - PubMed

LinkOut - more resources